Genoptix Sets IPO Terms

San Diego-based Genoptix, a provider of laboratory services for the hematology and oncology market, said this morning in a filing with the SEC that it will offer 5 million shares of its common stock for between $14.00 and $16.00 per share. The firm, which is looking to trade on the NASDAQ Global Market as GXDX, is venture backed by Enterprise Partners, Chicago Growth Partners, Wliliam Blair Capital Partners, Alliance Technology Ventures, Tullis-Dickerson Capital, Excelsio Venture Partners, and others. The firm's IPO is being underwritten by Lehman Brothers, Banc of America Securities, and Cowen and Company.